Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven
In this first part of a special two-episode series of TOGA's Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O'Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide. The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of 'once in a life time' rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient's individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. Resource Links: CM816 https://www.nejm.org/doi/full/10.1056... CM9LA https://www.thelancet.com/journals/la... CM227-https://www.nejm.org/doi/full/10.1056... CM227 was a clinical trial that examined ipi/nivo, nivo alone or chemotherapy in pts with NSCLC with PD-L1 expression level of 1% (00:00) Welcome and Acknowledgement (02:00) New PBS Listing Explained (04:18) Defining Advanced and Sensitive (07:18) Dual vs Single Immunotherapy (12:27) Early Stage and Recurrence (14:26) Duration Stopping and Restarting (20:57) Other Thoracic Cancers (23:55) System Impact and Wrap Up Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membe... Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/suppo... Follow Us LinkedIn: / thoracic-oncology-group-of-australasia X (Twitter): https://x.com/TOGAANZ Instagram: / togaanz YouTube: / @thoracic_oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

The Evolving Landscape of BRAF-Mutated NSCLC in Australia

The economist billionaires fear: this is how we get a wealth tax

The war on Iran showed limits of America's power abroad | Vali Nasr | The David Hearst Podcast

Water Trading

The REAL Cause of Dementia Men & Women NEED To Know

Astrophysicist WARNS: "You're Not Prepared For This"

Thymic Cancer: The Lesser-Known Thoracic Tumours

Justin Wolfers on the economic absurdities of Trump's America | That's Business with Alan Kohler

The AI Skills Nobody is Teaching (And Everyone Needs) | AI Expert Ethan Mollick

Peer2Peer: The Podcast | IOL Materials: What We Know Today

Spine Surgeon Drowns for 30 Minutes —Comes Back With a List

The new medical innovations that could change everything - The Engineers, BBC World Service

Thoracic Cancer International Highlights from ESMO, ASTRO & IMiG 2025

What Americans Need to Understand About China | The Ezra Klein Show

The Mitochondria Doctor: This Reverses Gray Hair, Makes You Feel Young Again & Fixes Disease!

Ivermectin to Treat Cancer? Get the FACTS

Ancient Human Species We Once Co-Existed With

Inside the Mind of an NHS Medical Director | What the Job REALLY Involves – The Right Chamber – E...

